In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 ...
Fifteen years ago, doctors in Europe noticed a remarkable thing happening in people with chronic hepatitis B infections. When ...
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results